10, 11. In the antitumor immunity, celecoxib treatment can promote the CD8+ CTL infiltration and reduce the FOXP3+ Treg recruitment in tumor tissues by IDO downregulation 12, 13. Moreover, celecoxib therapy can attenuate the M1 to M2 polarization and the PD‐L1 expression of TAMs 14, 15. The gene discussed is CD8A; the disease is neoplasm.